Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-12-27
2005-12-27
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000
Reexamination Certificate
active
06979680
ABSTRACT:
The present invention relates to the use of glycosaminoglycans having an average/molecular weight of 2,400 D for the preparation of pharmaceutical compositions suitable for the treatment of senile dementia, in particular for the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.
REFERENCES:
patent: 4351938 (1982-09-01), Barnett et al.
patent: 4847338 (1989-07-01), Linhardt et al.
patent: 4987222 (1991-01-01), De Ambrosi et al.
patent: 5084564 (1992-01-01), Vila et al.
patent: 0 293 974 (1988-12-01), None
patent: 0 450 508 (1991-10-01), None
patent: 0 450 508 (1991-10-01), None
Snow et al. “An Important Role of Heparan Sulfate Proteoglycan (Perlecan) in a Model System for the Deposition and Persistence of Fibrillar Aβ-Amyloid in Rat Brain” Neuron, vol. 12 pp. 219-234 (Jan. 1994).
George Perry et al., “Association of Heparan Sulfate Proteoglycan with the Neurofibrillary Tangles of Alzheimer's Disease”,The Journal of Neuroscience, vol. 11, pp. 3679-3683, Nov. 1991.
D.R. Hinton et al, “Optic Nerve Degeneration In Alzheimer's Disease”,J. Neuropathol. Exp Neurol, vol. 45, p. 340, May 1986.
R.N. Kalaria et al., “Acetylcholinesterase And Its Association With Heparan Sulphate Proteoglycans In Cortical Amyloid Deposits of Alzheimer's Disease”,Neuroscience, vol. 51, No. 1 pp. 177-184, 1992.
Stanley A. Lorens, Ph.D. et al., “Behavioral, Endocrine, and Neurochemical Effects of Sulfomucopolysaccharide Treatment in the Aged Fischer 344 Male Rat”,Seminars in Thrombosis and Hemostasis, vol. 17, Supplement 2, pp. 164-173, 1991.
Luciano Conti et al., “Alteroid In The Treatment of Dementia: Results of a Clinical Trial”,Mod Probl Pharmacopsychiatry, vol. 23, pp. 76-84, 1989.
Einar M. Sigurdsson et al., “Local and Distant Histopathological Effects of Unilateral Amyloid- 25-35 Injections Into the Amygdala of Young F344 Rats”, Neurobiology of Aging, vol. 17, No. 6, pp. 893-901, 1996.
Bruce A. Yankner et al., Neurotrophic and Neurotoxic Effects of Amyloid Protein: Reversal by Tachykinin Neuropeptides, ,Science, vol. 250, pp. 279-250, Oct. 1990.
Lucilla Pametti et al., “Glycosaminoglycan Polysulfate in Primary Degenerative Dementia”, Pilot Study if Biologic and Clinical Effects, ,Neuropsychobiology, vol. 31, pp. 76-80, 1995.
J.A. Doebler et al., “Hippocampal Neuronal RNA in Alzheimer's Disease”,J. Neuropathol Exp Neurol, vol. 45, p. 340, May 1986.
J.P. Willmer et al., “The Demonstration of Sulfated Glycosaminoglycans (GAGs) In Association With The Amyloidotic Lesions of Alzheimer's Diseases”,J. Neuropathol Exp Neurol, vol. 45, p. 340, May 1986.
Cornelli Umberto
De Ambrosi Luigi
Fareed Jawed
Hanin Israel
Lee John
Cornelli Umberto
Morgan & Finnegan L.L.P.
LandOfFree
Glycosaminoglycans having an average molecular weight of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosaminoglycans having an average molecular weight of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosaminoglycans having an average molecular weight of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3473993